metricas
covid
Annals of Hepatology Lactate/albumin ratio as an indicator of mortality in patients hospitalized with...
Journal Information
Vol. 30. Issue S1.
Abstracts Asociación Mexicana de Hepatología (AMH) 2024
(April 2025)
Vol. 30. Issue S1.
Abstracts Asociación Mexicana de Hepatología (AMH) 2024
(April 2025)
Full text access
Lactate/albumin ratio as an indicator of mortality in patients hospitalized with ACLF at the Juárez Hospital in Mexico.
Visits
242
G. Bretón-Arroy, LA. Robles-Casanova, M. Coutiño-Flores, MR. Herrero-Maceda, SMI. Mejia-Loza
Gastroenterology Department, Hospital Juárez, México City, Mexico
This item has received
Article information
Abstract
Full Text
Download PDF
Statistics
Figures (1)
Tables (1)
Table 1. Descriptive statistics of study population.
Tables
Special issue
This article is part of special issue:
Vol. 30. Issue S1

Abstracts Asociación Mexicana de Hepatología (AMH) 2024

More info
Introduction and Objectives

Albumin and lactate are markers of systemic inflammation, which are altered by their hepatic metabolism; however, they can be useful indicators of mortality in patients with cirrhosis. To determine the association between lactate/albumin ratio levels and mortality in patients with ACLF.

Materials and Patients

A retrospective and observational cohort study was conducted. Eighty-five patients diagnosed with ACLF according to the EASL-CLIF criteria were included from February 2022 to May 2024. Patients with hepatocellular carcinoma were excluded. Data analysis was performed using GraphPad Prism version 10.2.3 and Microsoft Excel software. An ROC curve was performed to establish the cutoff point of the lactate/albumin ratio, as well as determine the sensitivity and specificity of the model to predict 28-day mortality.

Results

Eighty-five patients were included, 68 (80%) men and 17 (20%) women; average age 52.4 years (39 -80). Alcohol consumption was the main cause of cirrhosis in 74 (87.05%), autoimmune diseases in 7 (8.23%), and MASLD in 4 (4.70%) (Table 1). 12 patients (14.11%) had ACLF grade 1, 29 (34.11%) grade 2 and 44 (51.76%) grade 3. With failure: kidney 61 (71.76%), liver 57 (67.05%), brain 49 (57.64%), coagulation 37 (43.52%), respiratory 15 (17.64%) and circulatory 5 (5.88%) (Table 1). 37 (43.52%) died within the first 28 days. The cutoff point of the lactate/albumin ratio was 1.74 (AUC 0.87), with a p value <0.0001, sensitivity 71.7% and specificity 58.8% (95% CI) (Figure 1).

Conclusions

The cutoff point of the lactate/albumin ratio of 1.74 allows for the objective prediction of mortality in patients with ACLF using easily accessible laboratory tests.

Full Text

Ethics statement: The protocol was registered and approved by the Ethics Committee. The identity of the patients is protected. Consent was obtained.

Declaration of interests: None.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Figure 1. Lactate/albumin ratio AUC.

Table 1.

Descriptive statistics of study population.

Age years  39- 80 
Sex:   
Male, N (%)  68 (80%) 
Female, N (%)  17 (20%) 
Cirrhosis etiology:   
Alcohol, N (%)  74 (87.05%) 
Autoimmune, N (%)  7 (8.23%) 
MAFLD, N (%)  4 (4.70%) 
ACLF:   
Grade 1, N (%)  12 (14.11%) 
Grade 2, N (%)  29 (34.11%) 
Grade 3, N (%)  44 (51.76%) 
Organ failure:   
Kidney, N (%)  61 (71.76%) 
Liver, N (%)  57 (67.05%) 
Brain, N (%)  49 (57.64%) 
Coagulation, N (%)  37 (43.52%) 
Respiratory, N (%)  15 (17.64%) 
Circulatory, N (%)  5 (5.88%) 

ACLF, acute-on-chronic liver failure; MAFLD, metabolic dysfunction-associated fatty liver disease.

Download PDF
Article options
Tools